Merck's $6.7B Terns Deal Clears Regulatory Hurdle
Merck has cleared a key regulatory hurdle in its plan to acquire clinical stage oncology company Terns Pharmaceuticals Inc. for $6.7 billion, the pharmaceutical giant said Friday. ...To view the full article, register now.
Already a subscriber? Click here to view full article